Us Vascular Access Devices Market Report: Market Size & Forecast 2026

The vascular access devices market covers peripherally and centrally inserted catheters, implanted ports, and needle-free connectors used for repeated venous access in inpatient, ambulatory, and homecare environments. In North America, the market stood at approximately $9.5 billion in 2026 and is growing at 5.6 percent annually, underpinned by widespread clinical adoption of long-term infusion therapies. The region commands the largest share of the global vascular access devices market, which was valued at roughly $8.6 billion in 2024 and is projected to reach $11.5 billion globally by 2030.

• •Market includes catheters (PICC, CVC, peripheral), needle-free connectors, and vascular ports for repeated IV access.
• •North America is the dominant regional segment of the global market.
• •Growth is tied to rising prevalence of chronic conditions requiring long-term intravenous therapy.

The primary engine of market expansion is the increasing prevalence of chronic diseases such as diabetes, obesity, and kidney disease that necessitate repeated venous access over extended treatment courses. An aging demographic is elevating the volume of inpatient and long-term care procedures, while a shift toward outpatient and home infusion environments broadens the addressable patient population. Additional support comes from clinical guidelines favoring catheter-based drug delivery and hospital-acquired infection prevention initiatives.

• •Rising incidence of diabetes, obesity, and end-stage renal disease drives higher demand for chronic venous access solutions.
• •Growing elderly population increases procedural volumes in hospitals, dialysis centers, and long-term care facilities.
• •Emphasis on reducing catheter-related bloodstream infections stimulates adoption of advanced, antimicrobial-equipped devices.

North America is segmented broadly into peripheral vascular access devices, central venous access devices, and accessory components such as needle-free connectors and extension sets. The United States constitutes the overwhelming majority of regional demand, supported by a mature hospital infrastructure, favorable reimbursement frameworks, and a high density of specialty care facilities. Canada represents a smaller but steadily growing segment, while Mexico offers emerging opportunity driven by healthcare modernization.

• •Central vascular access devices and peripherally inserted central catheters represent the largest product subcategories within North America.
• •The United States dominates regional revenue due to advanced healthcare infrastructure and widespread insurance coverage for vascular access procedures.
• •Homecare and ambulatory infusion settings are the fastest-growing distribution channels in the region.

Who are the notable companies in the industry?

The competitive structure reflects moderate consolidation, with the market served by a mix of large, diversified medical device producers offering broad portfolios and smaller specialty manufacturers focusing on niche vascular access technologies. Integrated producers typically control the full supply chain from raw material processing through final device assembly, while specialty firms compete on innovation in catheter materials and connection safety. Manufacturing capacity is concentrated predominantly in the United States and in a small number of international hubs that serve the North American supply chain.

• •Market shows moderate consolidation with a dual structure of large integrated device manufacturers and smaller specialty producers.
• •Integrated players operate end-to-end supply chains from medical-grade polymer and metal feedstock to finished sterile devices.
• •North American manufacturing and assembly capacity is heavily concentrated in the United States, with some capacity sourced from established international supply-chain hubs.

What are the recent trends and outlook?

Emerging product design trends emphasize antimicrobial surface coatings, pressure-activated needle-free connectors, and catheter materials engineered to reduce thrombogenicity and mechanical failure. Regulatory pressure around hospital-acquired infections is accelerating replacement cycles and incentivizing premium-priced advanced devices. Over the forecast horizon, the market is expected to continue its steady upward trajectory as aging demographics and the expansion of outpatient infusion therapy sustain procedural volumes across North America.

• •Antimicrobial and anti-thrombogenic coating technologies are key differentiators in new product launches.
• •Needle-free connector mandates and infection-prevention regulations are driving device upgrade cycles.
• •Growth in outpatient infusion and home-based chemotherapy is expanding the addressable market beyond traditional hospital settings.